Johnson & Johnson's orthopedics sales dip in Q4: 5 notes

Orthopedic

Johnson & Johnson on Jan. 24 posted $23.7 billion in 2022 revenue, a 4.4 percent decrease. Its orthopedic sales remained flat year-over-year, and its fourth-quarter orthopedic sales fell slightly.

Five things to know:

1. Orthopedic sales in the fourth quarter was $2.1 billion, a 0.4 percent decrease. Hip sales rose 1.7 percent year-over-year in the fourth quarter with $385 million, and knee sales grew 3.4 percent with $354 million.

2. Fourth quarter trauma sales fell 2.4 percent year-over-year with $710 million. The spine and sports medicine segments saw $699 million in fourth qarter sales, a 1.3 percent year-over-year decrease. 

3. Full-year orthopedic sales of $8.6 billion was the same compared to 2021 sales. 

4.  MedTech business as a whole brought in $6.8 billion on 2022, a 1.2 percent decrease from 2021.

5. Johnson & Johnson expects 2023 operational revenue to grow 3.5 percent. 

Copyright © 2025 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


You can unsubscribe from these communications at any time. For more information, please review our Privacy Policy.
 

Articles We Think You'll Like